Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4256901 | 0.88 | CYP3A4 (0.66) | CYP3A4MAPK1USP2SMN1; SMN2KMT2A | |
| SCHEMBL14992580 | 0.87 | SMN1; SMN2 (0.46) | CYP3A4MAPK1USP2SMN1; SMN2KMT2A | |
| SCHEMBL11816616 | 0.83 | ALDH1A1 (0.46) | CYP3A4MAPK1USP2SMN1; SMN2KMT2A | |
| SCHEMBL596707 | 0.83 | KDM4E (0.52) | CYP3A4MAPK1USP2SMN1; SMN2KMT2A | |
| SCHEMBL7282028 | 0.81 | CYP3A4 (0.55) | CYP3A4KMT2AMAPTKDM4EPOLB | |
| SCHEMBL14818820 | 0.78 | PLK1 (0.48) | CYP3A4SMN1; SMN2KMT2AMAPTKDM4E | |
| SCHEMBL28154597 | 0.78 | KMT2A (0.49) | CYP3A4KMT2APOLBHPGDTYK2 | |
| SCHEMBL27683482 | 0.78 | CYP3A4 (0.53) | CYP3A4MAPK1USP2SMN1; SMN2KMT2A | |
| SCHEMBL2093961 | 0.77 | KMT2A (0.44) | CYP3A4MAPK1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL19230364 | 0.76 | ABCG2 (0.39) | CYP3A4MAPK1USP2SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11071736-B2 | Modulators of HEC1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION | 2021-07-27 | — | — | US | disclosed |
| US-11071736-B2 | Modulators of HEC1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION | 2021-07-27 | — | — | US | disclosed |
| US-10588909-B2 | Modulators of HEC1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2020-03-17 | — | — | US | disclosed |
| EP-2785714-B1 | IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORP (TW) | 2018-11-21 | — | — | EP | disclosed |
| US-20180318310-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | DEVELOPMENT CENTER OF BIOTECHNOLOGY (TW) | 2018-11-08 | — | — | US | disclosed |
| US-20150250794-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORP (TW) | 2015-09-10 | — | — | US | disclosed |
| US-20150250794-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORP (TW) | 2015-09-10 | — | — | US | disclosed |
| US-20150250794-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORP (TW) | 2015-09-10 | — | — | US | disclosed |
| US-8999983-B2 | Modulators of Hec1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2015-04-07 | — | — | US | disclosed |
| US-8999983-B2 | Modulators of Hec1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2015-04-07 | — | — | US | disclosed |
| US-8999983-B2 | Modulators of Hec1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2015-04-07 | — | — | US | disclosed |
| EP-2785714-A1 | IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | Taivex Therapeutics Corporation (TW) | 2014-10-08 | — | — | EP | disclosed |
| US-20130190312-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORPORATION (TW) | 2013-07-25 | — | — | US | disclosed |
| US-20130190312-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORPORATION (TW) | 2013-07-25 | — | — | US | disclosed |
| US-20130190312-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORPORATION (TW) | 2013-07-25 | — | — | US | disclosed |
| WO-2013082324-A1 | IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORPORATION (TW) | 2013-06-06 | — | — | WO | disclosed |
| WO-2013082324-A1 | IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORPORATION (TW) | 2013-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180318310-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | WEE1, WEE2, NEK11 | CYP3A4 3983/4885MAPK1 1556/4885USP2 1461/4885 |
| US-20130190312-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | WEE1, WEE2, NEK11 | CYP3A4 3983/4885MAPK1 1556/4885USP2 1461/4885 |
| US-20150250794-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | WEE1, WEE2, NEK11 | CYP3A4 3983/4885MAPK1 1556/4885USP2 1461/4885 |
| US-10588909-B2 | Modulators of HEC1 activity and methods therefor | WEE1, WEE2, NEK11 | CYP3A4 3983/4885MAPK1 1556/4885USP2 1461/4885 |
| US-11071736-B2 | Modulators of HEC1 activity and methods therefor | WEE1, WEE2, NEK11 | CYP3A4 3983/4885MAPK1 1556/4885USP2 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.